NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted)
NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) has been granted full marketing authorisation by the EMA for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older in accordance with official recommendations. Nuvaxovid can be administered as booster dose approximately 6 months after the second dose in individuals 18 years of age and older.
Information on the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted)
If your enquiry is regarding the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted), you can find some useful information in the resource below.
Request Medical Information
Novavax is unable to provide medical advice regarding your health condition. Please consult your doctor, nurse or other healthcare provider, who is in the best position to advise you about the suitability of a particular treatment as they have access to the details of your medical history, as well as information on all medicinal products.
To ask Novavax Medical Information a question about a Novavax product please call
+49 800 1813940 between 09:00–17:00.
Report an Adverse Event (AE)
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Alternatively, adverse events of serious concern in association with a Novavax product can be reported to the Federal Institute for Drugs and Medical Devices at www.bfarm.de or to Novavax Pharmacovigilance at +49 800 1813940 or via the Novavax Adverse Event Reporting Form.
Report a Product Quality Complaint
If you have a product quality complaint related to a physical issue with a Novavax product or its packaging, please report the complaint via ONE of the following ways:
Option 1: Complete and submit a Product Quality Complaint Form by clicking on the button below.
Option 2: Call +49 800 1813940 between 09:00–17:00